Supplementary Figure 2 from Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide

crossref(2023)

引用 0|浏览20
暂无评分
摘要

Mutation profiles in ctDNA: truncating and/or pathogenic mutations in DDR or DDR-related pathway

更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要